Massey Documents by Type

Permanent URI for this communityhttps://mro.massey.ac.nz/handle/10179/294

Browse

Filters

2020 - 20242

Settings

Subject: search.filters.subject.Lung

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Birth weight and prematurity with lung function at ~17.5 years: "Children of 1997" birth cohort.
    (Springer Nature Limited, 2020-01-15) He B; Kwok MK; Au Yeung SL; Lin SL; Leung JYY; Hui LL; Li AM; Leung GM; Schooling CM
    We aimed to determine if prematurity and lower birth weight are associated with poorer lung function in a non-western developed setting with less marked confounding by socioeconomic position. Using multivariable linear regression in Hong Kong's "Children of 1997" birth cohort, adjusted associations of prematurity and birth weight with forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and forced expiratory flow at 25-75% of the pulmonary volume (FEF25-75%) at ~17.5 years were assessed. Associations for birth weight were stronger in boys for FEV1 (boys: 0.31 L, 95% confidence interval (CI) 0.24 to 0.38, girls: 0.18 L, 95% CI 0.12 to 0.25), FVC (boys: 0.36 L, 95% CI 0.27 to 0.44, girls: 0.22 L, 95% CI 0.15 to 0.28) and FEF25-75% (boys: 0.35 L, 95% CI 0.21 to 0.49, girls: 0.22 L, 95% CI 0.09 to 0.34) adjusted for age, socioeconomic position and infant and maternal characteristics. Similarly adjusted, preterm birth (compared to full-term birth) was associated with lower FEV1/FVC and FEF25-75%. Thus, associations of lower birth weight, especially in boys, and prematurity with poorer lung function at 17.5 years were found. Identifying underlying mechanism might contribute to the improvement of pulmonary health and the prevention of adult respiratory illness.
  • Thumbnail Image
    Item
    Nanoengineered polymers and other organic materials in lung cancer treatment: Bridging the gap between research and clinical applications
    (Elsevier Ltd, 2024-03-25) Jin X; Heidari G; Hua Z; Lei Y; Huang J; Wu Z; Paiva-Santos AC; Guo Z; Karimi Male H; Neisiany RE; Sillanpää M; Prakash C; Wang X; Tan Y; Makvandi P; Xu Y
    Cancer remains a major global health challenge, with increasing incidence and mortality rates projected for the coming years. Lung cancer, in particular, poses significant obstacles due to late-stage diagnosis and limited treatment options. While advancements in molecular diagnostics have been made, there is a critical need to connect the dots between laboratory and hospital for better lung cancer treatment. Systemic therapy plays a crucial role in treating advanced-stage lung cancer, and recent efforts have focused on developing innovative drug delivery techniques. Nanoparticles (NPs) have emerged as a promising approach to lung cancer treatment, offering enhanced drug delivery, active targeting, and reduced toxicity. Organic-based nanomaterials, like polymeric nanoparticles, solid lipid nanoparticles, and liposomes hold great potential in this field. This review examines the application of NPs in lung cancer treatment, highlights current therapies, explores organic nanoparticle-based approaches, and discusses limitations and future perspectives in clinical translation.